| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...9j3883M |
| P356 | DOI | 10.1371/JOURNAL.PONE.0103883 |
| P932 | PMC publication ID | 4138040 |
| P698 | PubMed publication ID | 25137181 |
| P5875 | ResearchGate publication ID | 264902810 |
| P50 | author | Armando Santoro | Q56335956 |
| P2093 | author name string | Franco Cuccurullo | |
| Antonio Marchetti | |||
| Fiamma Buttitta | |||
| Lara Felicioni | |||
| Maela Del Grammastro | |||
| Sara Malatesta | |||
| Lucio Crinò | |||
| Tommaso De Pas | |||
| Antonio Chella | |||
| Alba Ariela Brandes | |||
| Giampaolo Filice | |||
| Paola Venturino | |||
| Irene Centi | |||
| P2860 | cites work | Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer | Q21296854 |
| Isolation of rare circulating tumour cells in cancer patients by microchip technology | Q24597164 | ||
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 | ||
| Next-generation DNA sequencing methods | Q28285066 | ||
| Molecular biomarker analyses using circulating tumor cells | Q28749394 | ||
| Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. | Q54465286 | ||
| Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers. | Q54652248 | ||
| Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer | Q58282415 | ||
| Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival | Q79954604 | ||
| Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells | Q82043930 | ||
| Detection of mutations in EGFR in circulating lung-cancer cells | Q29615033 | ||
| Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer | Q30080026 | ||
| Isolation of circulating tumor cells using a microvortex-generating herringbone-chip | Q30497257 | ||
| Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology | Q31006508 | ||
| Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer | Q34122909 | ||
| Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. | Q34359601 | ||
| Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer | Q34790678 | ||
| Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer | Q35120911 | ||
| Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. | Q36491122 | ||
| Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer | Q36959162 | ||
| Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers | Q37438296 | ||
| Circulating Tumor Cells in Breast Cancer: Detection Systems, Molecular Characterization, and Future Challenges | Q37904507 | ||
| Pharmacogenetics of EGFR in Lung Cancer: Perspectives and Clinical Applications | Q38010747 | ||
| Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study | Q39660094 | ||
| Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. | Q44845388 | ||
| Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. | Q45986974 | ||
| Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer | Q46195110 | ||
| Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib | Q46504066 | ||
| Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer | Q47240978 | ||
| Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker | Q47404238 | ||
| Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer | Q48704229 | ||
| EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases | Q49089662 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | massive parallel sequencing | Q6784807 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | non-small-cell lung carcinoma | Q3658562 |
| P304 | page(s) | e103883 | |
| P577 | publication date | 2014-08-19 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment | |
| P478 | volume | 9 |
| Q38672934 | Advances in clinical next-generation sequencing: target enrichment and sequencing technologies |
| Q58780366 | Assessment of the Mutational Status of NSCLC Using Hypermetabolic Circulating Tumor Cells |
| Q41605032 | Biology and clinical significance of circulating tumor cell subpopulations in lung cancer |
| Q41605039 | Biophysical technologies for understanding circulating tumor cell biology and metastasis |
| Q47126156 | Blood-based tumor biomarkers in lung cancer for detection and treatment. |
| Q102063582 | CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries |
| Q33751043 | Cancer gene panel analysis of cultured circulating tumor cells and primary tumor tissue from patients with breast cancer |
| Q41605016 | Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer |
| Q89908179 | Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer |
| Q91679378 | Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer |
| Q38765748 | Circulating Tumor Cells: Back to the Future |
| Q50199981 | Circulating Tumor Cells: Markers and Methodologies for Enrichment and Detection. |
| Q90664749 | Circulating Tumour Cells in Lung Cancer |
| Q33618596 | Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review |
| Q92203830 | Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer |
| Q92263121 | Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review |
| Q28077340 | Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? |
| Q35159562 | Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation |
| Q47104064 | Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer |
| Q26781333 | Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions |
| Q53178108 | Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells |
| Q26781088 | Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer |
| Q36643142 | Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses |
| Q28082499 | Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer |
| Q26765357 | Evaluation and consequences of heterogeneity in the circulating tumor cell compartment |
| Q37468081 | Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis |
| Q35842078 | Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method. |
| Q64240595 | Isolation of circulating tumor cells and detection of EGFR mutations in patients with non-small-cell lung cancer |
| Q47153925 | Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology |
| Q38770935 | Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma |
| Q49740946 | Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer |
| Q39076207 | Liquid Biopsy in Non-Small Cell Lung Cancer |
| Q61548344 | Liquid biopsy and NSCLC |
| Q28076191 | Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring |
| Q38513661 | Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs |
| Q27340255 | Microfluidic enrichment for the single cell analysis of circulating tumor cells |
| Q39835396 | Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS. |
| Q47110464 | Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer |
| Q47354317 | Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration |
| Q37051546 | Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma |
| Q47159366 | New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA. |
| Q39114552 | Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line |
| Q34550417 | Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. |
| Q26801357 | Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer |
| Q45891469 | Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges. |
| Q26778913 | Notes for developing a molecular test for the full characterization of circulating tumor cells |
| Q64080618 | Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma |
| Q50992948 | Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer. |
| Q54977996 | RETRACTED: Identification of circulating tumor cells with EML4-ALK translocation using fluorescence in situ hybridization in advanced ALK-positive patients with lung cancer. |
| Q28070120 | Recent advances in the biology of human circulating tumour cells and metastasis |
| Q54120286 | Reliability of using circulating tumor cells for detecting epidermal growth factor receptor mutation status in advanced non-small-cell lung cancer patients: a meta-analysis and systematic review |
| Q51100178 | Retracing Circulating Tumour Cells for Biomarker Characterization after Enumeration |
| Q41605055 | Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer-ready for prime-time? |
| Q36746316 | Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells |
| Q88189997 | Strategies for Isolation and Molecular Profiling of Circulating Tumor Cells |
| Q41976096 | Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein |
| Q37244501 | Technological advances in precision medicine and drug development |
| Q39097813 | The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. |
| Q58781611 | The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer |
| Q64062553 | The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer |
| Q52363678 | The crucial role of multiomic approach in cancer research and clinically relevant outcomes. |
| Q64073628 | The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer |
| Q36849660 | The potential for liquid biopsies in the precision medical treatment of breast cancer |
| Q90724935 | Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements |
| Q26744100 | Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges |
| Q92643931 | Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival |
| Q47759918 | Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC. |
| Q64887576 | VTX-1 Liquid Biopsy System for Fully-Automated and Label-Free Isolation of Circulating Tumor Cells with Automated Enumeration by BioView Platform. |
| Q38408223 | Vertical Magnetic Separation of Circulating Tumor Cells for Somatic Genomic-Alteration Analysis in Lung Cancer Patients |
Search more.